fluticasone furoate/vilanterol vs Glycopyrrolate/formoterol fumarate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
fluticasone furoate/vilanterol · Breo Ellipta
Marketed by GlaxoSmithKline
NCT01313676 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 16,568 participants, with all-cause mortality as an objective clinical primary endpoint. However, the fluticasone furoate/vilanterol versus placebo comparison did not meet statistical significance (hazard ratio 0.878, p=0.137), and the record does not report a power calculation.
Reported efficacy
Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants (missed)
Result source: NCT01313676
Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere
Marketed by AstraZeneca
NCT03324607 · Phase 2/3 · completed
The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.
Reported efficacy
Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks): Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) (mixed)
Result source: NCT03324607
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/vilanterol | Glycopyrrolate/formoterol fumarate |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | —Not reported |
| Trough FEV1, change | —Not reported | —Not reported |
| SGRQ total, change | —Not reported | —Not reported |
| TDI focal score | —Not reported | —Not reported |
Moderate or severe exacerbations, annualised rate
- fluticasone furoate/vilanterol
- —Not reported
- Glycopyrrolate/formoterol fumarate
- —Not reported
Trough FEV1, change
- fluticasone furoate/vilanterol
- —Not reported
- Glycopyrrolate/formoterol fumarate
- —Not reported
SGRQ total, change
- fluticasone furoate/vilanterol
- —Not reported
- Glycopyrrolate/formoterol fumarate
- —Not reported
TDI focal score
- fluticasone furoate/vilanterol
- —Not reported
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. fluticasone furoate/vilanterol: 0 of 4 rows · Glycopyrrolate/formoterol fumarate: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Glycopyrrolate/formoterol fumarate |
|---|---|
| Dropout rate | 0%a NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 0%a NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result12.5% NCT03081156 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | — |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Glycopyrrolate/formoterol fumarate
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · Glycopyrrolate/formoterol fumarate's landscape